Clinical Trials · NCT06439056
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Nanexa AB
- Enrollment
- 12
- Start date
- May 2024
- Locations
- 1 site, Germany
- Primary endpoint
- To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes